Diaceutics (LSE:DXRX) Gross-Profit-to-Asset % : 46.77% (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Diaceutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Diaceutics's annualized Gross Profit for the quarter that ended in Jun. 2024 was £21.46 Mil. Diaceutics's average Total Assets over the quarter that ended in Jun. 2024 was £45.89 Mil. Therefore, Diaceutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 was 46.77%.

Diaceutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Diaceutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diaceutics Gross-Profit-to-Asset % Chart

Diaceutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

68.33

28.72

27.63

35.90

41.66

Diaceutics Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial										27.86	44.50	36.87	47.61	46.77

Competitive Comparison of Diaceutics's Gross-Profit-to-Asset %

For the Health Information Services subindustry, Diaceutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diaceutics's Gross-Profit-to-Asset % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Diaceutics's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Diaceutics Gross-Profit-to-Asset % Calculation

Diaceutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	19.706	/	( (48.256	+	46.344)	/ 2 )
	=	19.706	/	47.3
	=	41.66 %

Diaceutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Jun. 2024 ))	/ count )
	=	21.462	/	( (46.344	+	45.426)	/ 2 )
	=	21.462	/	45.885
	=	46.77 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Diaceutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Diaceutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Diaceutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Diaceutics PLC (LSE:DXRX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

7DC:Germany

Address

Kings Hall Health and Wellbeing Park, Dataworks, First Floor, Building Two, Antrim, Belfast, GBR, BT9 6GW

Website

https://www.diaceutics.com

Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides the pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine, enabled by DXRX The Diagnostic Network. DXRX is the diagnostic commercialization platform designed specifically for precision medicine, integrating multiple pipelines of real-world, real-time diagnostic testing data from a network of labs. These solutions are helping the pharma companies commercialize their precision medicines, enhance their return on investment and ultimately improve patients' lives.

Diaceutics Headlines

No Headlines